Aeolus Pharmaceuticl Stock Shares Owned By Institutions
| AOLS Stock | USD 0.0001 0.00 0.00% |
Aeolus Pharmaceuticl fundamentals help investors to digest information that contributes to Aeolus Pharmaceuticl's financial success or failures. It also enables traders to predict the movement of Aeolus Pink Sheet. The fundamental analysis module provides a way to measure Aeolus Pharmaceuticl's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aeolus Pharmaceuticl pink sheet.
Aeolus |
Aeolus Pharmaceuticl Company Shares Owned By Institutions Analysis
Aeolus Pharmaceuticl's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 0.0% of Aeolus Pharmaceuticl are shares owned by institutions. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The shares owned by institutions for all United States stocks is 100.0% higher than that of the company.
Aeolus Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aeolus Pharmaceuticl's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aeolus Pharmaceuticl could also be used in its relative valuation, which is a method of valuing Aeolus Pharmaceuticl by comparing valuation metrics of similar companies.Aeolus Pharmaceuticl is currently under evaluation in shares owned by institutions category among its peers.
Aeolus Fundamentals
| Return On Equity | -1.86 | |||
| Return On Asset | -0.9 | |||
| Operating Margin | (5.31) % | |||
| Current Valuation | 167.29 K | |||
| Shares Outstanding | 152.09 M | |||
| Price To Earning | (2.37) X | |||
| Price To Book | 0.81 X | |||
| Price To Sales | 0.22 X | |||
| Revenue | 2.08 M | |||
| Gross Profit | (805 K) | |||
| EBITDA | (3.85 M) | |||
| Net Income | (3.56 M) | |||
| Cash And Equivalents | 403 K | |||
| Debt To Equity | 0.30 % | |||
| Current Ratio | 1.30 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (3.11 M) | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 1.25 | |||
| Beta | -3.96 | |||
| Market Capitalization | 167.29 K | |||
| Total Asset | 4.17 M | |||
| Retained Earnings | (184.68 M) | |||
| Working Capital | 3.16 M | |||
| Current Asset | 4.13 M | |||
| Current Liabilities | 972 K | |||
| Z Score | -61.6 | |||
| Net Asset | 4.17 M |
About Aeolus Pharmaceuticl Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aeolus Pharmaceuticl's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aeolus Pharmaceuticl using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aeolus Pharmaceuticl based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aeolus Pink Sheet Analysis
When running Aeolus Pharmaceuticl's price analysis, check to measure Aeolus Pharmaceuticl's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aeolus Pharmaceuticl is operating at the current time. Most of Aeolus Pharmaceuticl's value examination focuses on studying past and present price action to predict the probability of Aeolus Pharmaceuticl's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aeolus Pharmaceuticl's price. Additionally, you may evaluate how the addition of Aeolus Pharmaceuticl to your portfolios can decrease your overall portfolio volatility.